Sunosi Shortage: What Providers and Prescribers Need to Know in 2026

Patients prescribed Sunosi (solriamfetol) for narcolepsy or obstructive sleep apnea (OSA)-related excessive daytime sleepiness (EDS) are increasingly reporting difficulty filling their prescriptions. While Sunosi is not currently on the FDA's official drug shortage list, localized stocking gaps are common. This guide is designed to help sleep specialists, neurologists, psychiatrists, and primary care providers navigate the current landscape and support affected patients.

Current Status: No Official FDA Shortage, But Availability Varies

As of 2026, Sunosi does not appear on the FDA drug shortage database. Axsome Therapeutics (current U.S. distributor) has not issued any shortage advisories. However, clinical practices in multiple regions report patient complaints about local pharmacy stock gaps. This is likely driven by Sunosi's brand-only status (no generic until approximately 2042), Schedule IV classification, and the conservative ordering practices many retail pharmacies apply to expensive specialty controlled substances.

Pharmacological Profile: Rapid Review for Prescribers

Sunosi (solriamfetol) is a selective dopamine and norepinephrine reuptake inhibitor (DNRI). Its mechanism differs from modafinil (which primarily inhibits dopamine reuptake) and pitolisant (which acts on histamine H3 receptors). Solriamfetol also demonstrates TAAR1 agonist activity at clinically relevant concentrations, which may contribute to its wakefulness-promoting effects.

Approved indications: EDS associated with narcolepsy or OSA in adults (FDA-approved March 2019)

Dosing: 75 mg once daily (narcolepsy start); 37.5 mg once daily (OSA start); maximum 150 mg/day

DEA schedule: Schedule IV (CIV)

Key pharmacokinetics: ~95% oral bioavailability; Tmax ~2 hours; half-life ~7.1 hours; predominantly renally eliminated; minimal metabolism

Key contraindication: Concurrent or recent use (within 14 days) of MAOIs — risk of hypertensive reaction

Evidence Base: How Sunosi Stacks Up Against Alternatives

A 2023 systematic review and network meta-analysis published in Annals of Internal Medicine (Pitre et al.) compared wakefulness-promoting agents for OSA-associated EDS. The analysis found that solriamfetol was "likely superior" to modafinil/armodafinil and pitolisant on Epworth Sleepiness Scale (ESS) scores at 4 weeks, with high certainty evidence showing improvement vs. placebo (mean ESS difference: −3.85; 95% CI: −5.24 to −2.5). However, solriamfetol was also associated with higher discontinuation rates due to adverse events (anxiety, headache, insomnia), underscoring the importance of individualized treatment decisions.

Clinical Alternatives When Sunosi Is Unavailable

If a patient cannot access Sunosi, the following alternatives may be considered depending on the indication:

Modafinil (Provigil, generic): FDA-approved for narcolepsy, OSA, and SWSD. Generic widely available; Tier 1–2 on most formularies. First-line for most insurance step therapy.

Armodafinil (Nuvigil, generic): FDA-approved for narcolepsy, OSA, and SWSD. Longer half-life (~15 hours vs. modafinil's ~12 hours). Generic available.

Pitolisant (Wakix): Not a controlled substance; FDA-approved for EDS and cataplexy in narcolepsy (not OSA). H3 receptor antagonist/agonist mechanism. QT prolongation risk — check baseline ECG.

Sodium oxybate / low-sodium oxybate (Xyrem / Xywav): Schedule III/I (REMS program); nighttime dosing; approved for narcolepsy with/without cataplexy; Xywav also approved for idiopathic hypersomnia.

Navigating Insurance Prior Authorization for Sunosi

Prior authorization (PA) is required for Sunosi by most commercial payers, Medicare Advantage plans, and Medicaid. Common criteria include:

Confirmed diagnosis of narcolepsy (ICD-10: G47.41) or OSA (ICD-10: G47.33)

For OSA: documented adequate CPAP use for at least 1 month prior to Sunosi initiation

For OSA: prior trial and inadequate response to generic modafinil or armodafinil (step therapy)

Prescription from or in consultation with a sleep disorder specialist, neurologist, or psychiatrist (some payers require this)

PA approvals are typically granted for 12 months, with reauthorization requiring documentation of clinical response.

Patient Support Resources from Axsome

Axsome Therapeutics offers several resources to support access:

SUNOSI On My Side Program: Dedicated specialists to help patients navigate insurance coverage and financial assistance

Savings card: Eligible commercially insured patients can pay as little as $9 for up to a 90-day supply

Free trial voucher: 30-tablet one-time trial for patients with a valid prescription (available via pharmacist)

Samples: Prescribers can request samples directly through Axsome's HCP portal at sunosihcp.com

How medfinder Can Support Your Patients

medfinder is a service that helps patients locate which pharmacies near them have their medications in stock. When you prescribe Sunosi to a patient who may struggle to find it, recommending medfinder can save them hours of frustrating phone calls. Visit medfinder.com/providers to learn how medfinder supports your practice.